Veracyte, Inc. (VCYT)

$19.31

-0.17

(-0.87%)▲

Market is closed - opens 7 PM, 29 Apr 2024

Insights on Veracyte, Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 90.10M → 98.19M (in $), with an average increase of 8.2% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -29.61M → -28.29M (in $), with an average increase of 4.7% per quarter

  • Vs IQV

    In the last 1 year, Iqvia Holdings Inc. has given 23.2% return, outperforming this stock by 34.5%

  • Vs TMO

    In the last 3 years, Thermo Fisher Scientific, Inc. has given 0.2% return, outperforming this stock by 61.7%

Performance

  • $19.16
    $19.76
    $19.31
    downward going graph

    0.78%

    Downside

    Day's Volatility :3.04%

    Upside

    2.28%

    downward going graph
  • $18.61
    $30.52
    $19.31
    downward going graph

    3.63%

    Downside

    52 Weeks Volatility :39.02%

    Upside

    36.73%

    downward going graph

Returns

PeriodVeracyte, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-25.88%
0.5%
0.0%
6 Months
-4.6%
11.7%
0.0%
1 Year
-11.33%
6.2%
2.2%
3 Years
-61.55%
13.5%
-23.0%

Highlights

Market Capitalization
1.5B
Book Value
$14.25
Earnings Per Share (EPS)
-1.02
PEG Ratio
0.0
Wall Street Target Price
30.83
Profit Margin
-20.61%
Operating Margin TTM
0.15%
Return On Assets TTM
-0.99%
Return On Equity TTM
-7.02%
Revenue TTM
361.1M
Revenue Per Share TTM
4.97
Quarterly Revenue Growth YOY
22.3%
Gross Profit TTM
195.0M
EBITDA
9.3M
Diluted Eps TTM
-1.02
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.3
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
-0.09
EPS Estimate Next Quarter
-0.09

Analyst Recommendation

Buy
    73%Buy
    20%Hold
    6%Sell
Based on 15 Wall street analysts offering stock ratings for Veracyte, Inc.(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
3
3
3
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 59.66%

Current $19.31
Target $30.83

Company Financials

FY18Y/Y Change
Revenue
92.0M
↑ 27.87%
Net Income
-23.0M
↓ 25.82%
Net Profit Margin
-25.0%
↑ 18.09%
FY19Y/Y Change
Revenue
120.4M
↑ 30.82%
Net Income
-16.5M
↓ 28.34%
Net Profit Margin
-13.69%
↑ 11.31%
FY20Y/Y Change
Revenue
117.5M
↓ 2.4%
Net Income
-35.8M
↑ 117.51%
Net Profit Margin
-30.51%
↓ 16.82%
FY21Y/Y Change
Revenue
219.5M
↑ 86.85%
Net Income
-75.6M
↑ 110.79%
Net Profit Margin
-34.42%
↓ 3.91%
FY22Y/Y Change
Revenue
296.5M
↑ 35.09%
Net Income
-36.6M
↓ 51.62%
Net Profit Margin
-12.33%
↑ 22.09%
FY23Y/Y Change
Revenue
361.1M
↑ 21.76%
Net Income
-74.4M
↑ 103.51%
Net Profit Margin
-20.61%
↓ 8.28%
Q3 FY22Q/Q Change
Revenue
75.6M
↑ 3.74%
Net Income
-8.7M
↓ 8.49%
Net Profit Margin
-11.54%
↑ 1.54%
Q4 FY22Q/Q Change
Revenue
80.3M
↑ 6.22%
Net Income
-3.8M
↓ 55.93%
Net Profit Margin
-4.79%
↑ 6.75%
Q1 FY23Q/Q Change
Revenue
82.4M
↑ 2.65%
Net Income
-5.7M
↑ 47.87%
Net Profit Margin
-6.9%
↓ 2.11%
Q2 FY23Q/Q Change
Revenue
90.3M
↑ 9.58%
Net Income
-8.4M
↑ 47.82%
Net Profit Margin
-9.3%
↓ 2.4%
Q3 FY23Q/Q Change
Revenue
90.1M
↓ 0.24%
Net Income
-29.6M
↑ 252.51%
Net Profit Margin
-32.87%
↓ 23.57%
Q4 FY23Q/Q Change
Revenue
98.2M
↑ 8.98%
Net Income
-28.3M
↓ 4.47%
Net Profit Margin
-28.81%
↑ 4.06%
FY18Y/Y Change
Total Assets
120.6M
↑ 53.35%
Total Liabilities
40.9M
↓ 1.35%
FY19Y/Y Change
Total Assets
275.2M
↑ 128.13%
Total Liabilities
35.8M
↓ 12.54%
FY20Y/Y Change
Total Assets
457.2M
↑ 66.11%
Total Liabilities
35.9M
↑ 0.49%
FY21Y/Y Change
Total Assets
1.2B
↑ 159.83%
Total Liabilities
91.3M
↑ 154.13%
FY22Y/Y Change
Total Assets
1.2B
↓ 2.64%
Total Liabilities
81.2M
↓ 11.05%
FY23Y/Y Change
Total Assets
1.1B
↓ 1.61%
Total Liabilities
93.7M
↑ 15.39%
Q3 FY22Q/Q Change
Total Assets
1.1B
↓ 5.21%
Total Liabilities
77.8M
↓ 14.82%
Q4 FY22Q/Q Change
Total Assets
1.2B
↑ 2.71%
Total Liabilities
81.2M
↑ 4.43%
Q1 FY23Q/Q Change
Total Assets
1.2B
↑ 0.06%
Total Liabilities
75.9M
↓ 6.6%
Q2 FY23Q/Q Change
Total Assets
1.2B
↑ 0.35%
Total Liabilities
78.4M
↑ 3.34%
Q3 FY23Q/Q Change
Total Assets
1.1B
↓ 3.12%
Total Liabilities
70.9M
↓ 9.58%
Q4 FY23Q/Q Change
Total Assets
1.1B
↑ 1.14%
Total Liabilities
93.7M
↑ 32.21%
FY18Y/Y Change
Operating Cash Flow
-13.5M
↓ 43.46%
Investing Cash Flow
-1.9M
↑ 56.82%
Financing Cash Flow
59.5M
↓ 27393.12%
FY19Y/Y Change
Operating Cash Flow
-3.2M
↓ 76.1%
Investing Cash Flow
-42.7M
↑ 2180.31%
Financing Cash Flow
127.3M
↑ 113.93%
FY20Y/Y Change
Operating Cash Flow
-9.7M
↑ 200.46%
Investing Cash Flow
-3.8M
↓ 91.02%
Financing Cash Flow
203.6M
↑ 59.95%
FY21Y/Y Change
Operating Cash Flow
-31.6M
↑ 225.62%
Investing Cash Flow
-739.2M
↑ 19165.21%
Financing Cash Flow
596.3M
↑ 192.9%
FY22Y/Y Change
Operating Cash Flow
7.5M
↓ 123.83%
Investing Cash Flow
-29.4M
↓ 96.02%
Financing Cash Flow
3.5M
↓ 99.41%
Q3 FY22Q/Q Change
Operating Cash Flow
7.0M
↓ 2035.54%
Investing Cash Flow
8.8M
↓ 194.63%
Financing Cash Flow
1.5M
↓ 2081.33%
Q4 FY22Q/Q Change
Operating Cash Flow
9.7M
↑ 38.68%
Investing Cash Flow
-26.4M
↓ 400.15%
Financing Cash Flow
93.0K
↓ 93.74%
Q1 FY23Q/Q Change
Operating Cash Flow
-2.2M
↓ 122.29%
Investing Cash Flow
24.1M
↓ 191.09%
Financing Cash Flow
1.7M
↑ 1711.83%
Q2 FY23Q/Q Change
Operating Cash Flow
16.7M
↓ 867.54%
Investing Cash Flow
-3.7M
↓ 115.24%
Financing Cash Flow
397.0K
↓ 76.44%

Technicals Summary

Sell

Neutral

Buy

Veracyte, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Veracyte, Inc.
Veracyte, Inc.
-7.94%
-4.6%
-11.33%
-61.55%
-16.68%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-7.79%
23.1%
1.62%
-12.39%
110.45%
Agilent Technologies Inc.
Agilent Technologies Inc.
-5.57%
30.74%
2.44%
-0.71%
76.14%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
0.51%
29.89%
7.24%
15.73%
109.26%
Danaher Corp.
Danaher Corp.
-1.07%
26.91%
5.73%
-4.77%
87.73%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-5.55%
26.87%
23.16%
0.24%
68.7%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Veracyte, Inc.
Veracyte, Inc.
NA
NA
0.0
-0.3
-0.07
-0.01
NA
14.25
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
49.03
49.03
4.75
11.13
0.81
0.23
NA
17.88
Agilent Technologies Inc.
Agilent Technologies Inc.
32.89
32.89
2.7
5.5
0.21
0.08
0.01
21.12
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
37.35
37.35
2.81
21.53
0.13
0.05
0.0
120.87
Danaher Corp.
Danaher Corp.
45.86
45.86
3.13
7.63
0.08
0.04
0.0
72.16
Iqvia Holdings Inc.
Iqvia Holdings Inc.
32.05
32.05
1.33
11.11
0.23
0.05
NA
33.67
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Veracyte, Inc.
Veracyte, Inc.
Buy
$1.5B
-16.68%
NA
-20.61%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$41.1B
110.45%
49.03
23.08%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$40.8B
76.14%
32.89
18.35%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$220.4B
109.26%
37.35
13.99%
Danaher Corp.
Danaher Corp.
Buy
$185.5B
87.73%
45.86
18.55%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$42.6B
68.7%
32.05
9.06%

Institutional Holdings

  • ARK Investment Management LLC

    10.20%

  • BlackRock Inc

    9.54%

  • Vanguard Group Inc

    9.48%

  • Wellington Management Company LLP

    9.42%

  • Dimensional Fund Advisors, Inc.

    4.49%

  • Artisan Partners Limited Partnership

    4.29%

Corporate Announcements

  • Veracyte, Inc. Earnings

    Veracyte, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

veracyte is a pioneering genomic diagnostics company. our tests are dramatically improving clinical outcomes for patients by resolving inconclusive results from traditional diagnostic methods. we ask the right questions to resolve ambiguity and bring assurance to light, rendering tens of thousands of costly and unnecessary surgeries truly unnecessary. we are giving patients a clearer path forward. through scientific rigor we employ the best tools, best science and best minds to create tests that enable a more accurate diagnosis without the need for risky, costly and often unnecessary surgery. veracyte consistently brings to bear evidence that is unprecedented in genomic tests, thereby changing today's clinical practice standards. we are making a difference in the lives of physicians and patients. we are doing something real. .

Organization
Veracyte, Inc.
Employees
815
CEO
Mr. Marc A. Stapley
Industry
Health Technology

Discover More

FAQs